On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma

On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma

Noninvasive fibrosis indices can help stratify the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) receiving nucleos(t)ide analogue (NA) therapy. We investigated the predictive performance of on-treatment changes in FIB-4 (△FIB-4) and 1-year FIB-4 values (FIB-4 12M)...

Full description

Bibliographic Details
Main Authors: Hung-Wei Wang, Hsueh-Chou Lai, Tsung-Hui Hu, Wen-Pang Su, Sheng-Nan Lu, Chia-Hsin Lin, Chao-Hung Hung, Po-Heng Chuang, Jing-Houng Wang, Mei-Hsuan Lee, Chien-Hung Chen, Cheng-Yuan Peng
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
chronic hepatitis B
entecavir
hepatocellular carcinoma
fibrosis-4 (FIB-4)
noninvasive fibrosis index
Online Access:https://www.mdpi.com/2072-6694/12/5/1177

Internet

https://www.mdpi.com/2072-6694/12/5/1177

Similar Items